iiinova — where your digital self keeps evolving

Decera Clinical Insights @deceraclinicalins.bsky.social · 01/10/2026

In this episode of Oncology Unscripted by Decera Clinical Insights, John Marshall, MD, speaks with evolutionary biologist Daniel E. Lieberman, PhD, about how the way we eat has changed and what that could mean for our health. ▶️ Tune in to the full conversation: bit.ly/3ZDiQBg

010

Decera Clinical Insights @deceraclinicalins.bsky.social · 29/09/2026

Treatment burden can extend beyond the therapy itself for older adults with multiple myeloma. In #HematologyHighlights by Decera Clinical Insights, Dr Larysa Sanchez and Dr Joshua Richter discuss reducing appointment and dosing burdens for older patients. 🎧 Watch: bit.ly/4wGOqgx

000

Decera Clinical Insights @deceraclinicalins.bsky.social · 25/09/2026

The conversation around vaccines continues to evolve, with changing recommendations and growing public debate adding new complexity. Watch Oncology Unscripted here: shttps://bit.ly/4amh2md

010

Decera Clinical Insights @deceraclinicalins.bsky.social · 22/09/2026

Clinical trials don’t always reflect the older, frailer patients seen in everyday practice. In #HematologyHighlights by Decera Clinical Insights, Dr Joshua Richter and Dr Larysa Sanchez discuss translating trial data into individualized multiple myeloma care. 🎧 bit.ly/4wGOqgx

000

Decera Clinical Insights @deceraclinicalins.bsky.social · 17/09/2026

GLP-1 receptor agonist use has risen dramatically, but what happens when patients stop taking them, and what could widespread, long-term use mean for health outcomes? In Oncology Unscripted, John Marshall, MD, reflects on the rapid rise of GLP-1s and more! bit.ly/4amh2md

000

Decera Clinical Insights @deceraclinicalins.bsky.social · 15/09/2026

How can CAR T-cell and bispecific therapies be tailored for older adults with multiple myeloma? In #HematologyHighlights by Decera Clinical Insights, Dr Larysa Sanchez and Dr Joshua Richter discuss neurologic toxicities, infection risk, caregiver support, and more. 🎧 bit.ly/4wGOqgx

000

Decera Clinical Insights @deceraclinicalins.bsky.social · 14/09/2026

“Go exercise” may sound like simple advice, but helping patients become more physically active is far more complex. Dr. Marshall, sits down with evolutionary biologist Daniel E. Lieberman, PhD, to explore why physical activity can be so difficult and more: bit.ly/4amh2md

000

Decera Clinical Insights @deceraclinicalins.bsky.social · 09/09/2026

From AI-created viruses to mRNA vaccines showing promise in melanoma, scientific innovation continues to raise new questions, and new possibilities. Watch the full episode for Dr Marshall’s take on what these developments could mean for the future of cancer care: bit.ly/3ZDiQBg

020

Decera Clinical Insights @deceraclinicalins.bsky.social · 08/09/2026

Age alone doesn’t define what’s possible in multiple myeloma treatment. In #HematologyHighlights by Decera Clinical Insights, Dr Joshua Richter and Dr Larysa Sanchez discuss real-world treatment strategies for older adults with multiple myeloma. 🎧Watch the full episode: bit.ly/4wGOqgx

000

Decera Clinical Insights @deceraclinicalins.bsky.social · 04/09/2026

In this episode of Oncology Unscripted by Decera Clinical Insights, John Marshall, MD, reflects on the changing conversation around vaccines and explores new reports on a personalized mRNA vaccine for melanoma. 🔗 Watch the full episode: bit.ly/3ZDiQBg #Oncology #Melanoma #mRNA

010

Decera Clinical Insights @deceraclinicalins.bsky.social · 31/08/2026

Every treatment decision shapes what comes next. In Hematology Highlights by Decera Clinical Insights, Dr. Joshua Richter discusses why treating relapsed/refractory multiple myeloma is a long-term strategy. Watch: bit.ly/45d9b7k #MultipleMyeloma #HematologyHighlights

000

Decera Clinical Insights @deceraclinicalins.bsky.social · 28/08/2026

Emerging therapies continue to expand the treatment landscape for multiple myeloma. Watch: bit.ly/4wGOqgx #MultipleMyeloma #Hematology #Oncology #CELMoDs

000

Decera Clinical Insights @deceraclinicalins.bsky.social · 21/08/2026

What makes bispecific antibodies different from CAR T-cell therapy? Watch the full episode of #HematologyHighlights to learn more: bit.ly/45LYGIc #MultipleMyeloma #Hematology #Oncology #BispecificAntibodies

000

Decera Clinical Insights @deceraclinicalins.bsky.social · 07/08/2026

Hematology Highlights by Decera Clinical Insights, Dr. Richter discusses treatment strategies for patients with relapsed/refractory multiple myeloma who are ineligible for or decline T-cell redirection therapies, including CAR T-cell therapy and bispecific antibodies. Watch: bit.ly/4wGOqgx

000

Decera Clinical Insights @deceraclinicalins.bsky.social · 17/07/2026

In this episode of Hematology Unscripted by Decera Clinical Insights, Dr. Joshua Richter explores how to manage patients with multiple myeloma in the critical period leading up to CAR T-cell therapy. Watch: bit.ly/3Rhp8pD #MultipleMyeloma #CARTCellTherapy #HematologyUnscripted

000

Decera Clinical Insights @deceraclinicalins.bsky.social · 08/07/2026

Hematology Unscripted by Decera Clinical Insights explores the complex decisions clinicians face in treating blood cancers. Follow the series for evidence-informed conversations on multiple myeloma, CAR T-cell therapy, bispecific antibodies, sequencing strategies, and more. bit.ly/3Rhp8pD

000

Decera Clinical Insights @deceraclinicalins.bsky.social · 03/07/2026

As MRD ctDNA testing evolves, could it help guide more personalized treatment approaches in early breast cancer? John Marshall, MD, and Marija Balic, MD, discuss emerging data, assay sensitivity, and what may be possible in the future. Watch here: bit.ly/3ZDiQBg

000

Decera Clinical Insights @deceraclinicalins.bsky.social · 01/07/2026

Hematology Unscripted by Decera Clinical Insights is here. Hosted by Dr. Joshua Richter, this new series explores the complex decisions clinicians face in blood cancer care, from CAR T-cell therapy and bispecifics to sequencing and bridging strategies. Stay tuned: bit.ly/3Rhp8pD

000

Decera Clinical Insights @deceraclinicalins.bsky.social · 30/06/2026

In the latest episode of Oncology Unscripted, Dr. Marshall, discusses why biomarker testing is becoming an essential component of cancer care, the growing role of MRD and ctDNA testing, and emerging research that may further expand the impact of precision oncology. Watch: bit.ly/3ZDiQBg

000

Decera Clinical Insights @deceraclinicalins.bsky.social · 26/06/2026

MRD ctDNA testing is generating significant interest in early breast cancer care. In this episode of Oncology Unscripted, John Marshall, MD, and Marija Balic, MD, discuss the potential role of MRD testing and where the science is headed next. Watch here: bit.ly/4amh2md

000

Decera Clinical Insights @deceraclinicalins.bsky.social · 23/06/2026

Precision medicine is becoming a standard part of cancer care. In the latest #OncologyUnscripted episode, John Marshall, MD, discusses how ctDNA and MRD testing are shaping treatment decisions today—and the potential of blood-based cancer screening in the future. Watch: bit.ly/2GmLq22

000

Decera Clinical Insights @deceraclinicalins.bsky.social · 19/06/2026

Catch up on the latest episodes of Oncology Unscripted with John Marshall, MD 🎙️ Explore the expanding role of precision medicine, the impact of AI in cancer care, and key trends shaping the future of oncology. Watch 👉 bit.ly/3ZDiQBg #Oncology #OncologyInsights #ScientificActivation

000

Decera Clinical Insights @deceraclinicalins.bsky.social · 15/06/2026

“There’s no way around it anymore.” Precision medicine is now standard of care. #OncologyUnscripted by Decera Clinical Insights 🎧 Episode 30: bit.ly/3ZDiQBg #Oncology #EvidenceToAction #ScientificActivation #DecodingScience

000

Decera Clinical Insights @deceraclinicalins.bsky.social · 12/05/2026

AI is rapidly expanding its role in oncology, but it’s also raising important questions. From precision medicine to real-time health monitoring, the possibilities are expanding—but so is the need for thoughtful oversight. 🔗 Watch the full episode: bit.ly/3ZDiQBg

000

Decera Clinical Insights @deceraclinicalins.bsky.social · 08/05/2026

“Telepresence is not the same as presence.” In this episode of Oncology Unscripted, De John Marshall reflects on what AI can’t replace in cancer care. AI is here to stay. The question is how we preserve what makes care human. 🔗 Watch the episode: bit.ly/3ZDiQBg #AIinHealthcare

000

Decera Clinical Insights @deceraclinicalins.bsky.social · 05/05/2026

In this episode of Oncology Unscripted John Marshall, MD is joined by Neel Trivedi, MD; Ross Filice, MD; and Torbjørn Furuseth, MD to explore how AI is being used today and where it may be headed next. 🎉 Watch the full episode: bit.ly/3ZDiQBg

000

Decera Clinical Insights @deceraclinicalins.bsky.social · 01/05/2026

AI is rapidly reshaping cancer care, but where do we draw the line? In this episode of #OncologyUnscripted, Dr Marshall explores both the promise and the pressure of AI in oncology, from predicting treatment responses and supporting clinical trials and more! 🔗 Watch here: bit.ly/3ZDiQBg

000

Decera Clinical Insights @deceraclinicalins.bsky.social · 24/04/2026

Catch up on the latest Oncology Unscripted episodes with Dr. John Marshall 🍃 👉 bit.ly/3ZDiQBg #Oncology #CancerCare #GICancer #OncologyInsights

000

Decera Clinical Insights @deceraclinicalins.bsky.social · 20/04/2026

Cancer doesn’t evolve slowly anymore. As treatments advance, cancer adapts, often faster than we expect. While AI is reshaping care, they’re also raising an important question: What role does the physician play in a rapidly evolving, tech-driven future? 👉 Watch: bit.ly/3ZDiQBg

000

Decera Clinical Insights @deceraclinicalins.bsky.social · 15/04/2026

What does leadership in oncology look like over time? Sometimes, it’s believing in something before the field catches up. Dr. Marshall and Dr. Weiner reflect on the early days of immunotherapy and what it takes to stay committed to a vision. Watch the full discussion: bit.ly/3ZDiQBg

021

Decera Clinical Insights @deceraclinicalins.bsky.social · 07/04/2026

Standing in the Galápagos, it’s hard not to think about evolution, and what it means for oncology. Dr. John Marshall connects a recent cholangiocarcinoma study to the global evolution of cancer research and care. bit.ly/3ZDiQBg #OncologyUnscripted #CancerCare

022

Decera Clinical Insights @deceraclinicalins.bsky.social · 02/04/2026

Leadership in oncology is constantly evolving. In this conversation, Dr. John Marshall and Dr. Louis Weiner reflect on leading through change, advancing innovation, and the impact of immunotherapy. Watch the full discussion: bit.ly/3ZDiQBg #ClinicalInsights #Oncology

020

Decera Clinical Insights @deceraclinicalins.bsky.social · 19/03/2026

What’s happening at the FDA right now? In this #OncologyUnscripted clip, Dr. John Marshall discusses staffing cuts, leadership turnover, and structural changes, and what it could mean for cancer innovation and access to new therapies. ▶️ Watch the clip: bit.ly/3OIu1Xk

000

Decera Clinical Insights @deceraclinicalins.bsky.social · 10/03/2026

What happens to cancer care when instability hits the systems that support drug development and approval? Dr. Marshall discusses growing uncertainty at the FDA, from job cuts to leadership turnover and structural changes, and more! Watch: bit.ly/3OIu1Xk

000

Decera Clinical Insights @deceraclinicalins.bsky.social · 06/03/2026

$25 trillion. That’s the projected global cost of cancer care over the next 30 years, while many patients still lack access to basic treatment. Are we expanding access… or just escalating costs? New episode of #OncologyUnscripted: bit.ly/4aWDGAT

000

Decera Clinical Insights @deceraclinicalins.bsky.social · 02/03/2026

Cancer incidence is rising, breast, prostate, young-onset colon cancer, melanoma. Yet mortality has fallen >30%. Global cancer costs may reach $25T. We’re curing more patients, but funding threats put progress at risk. Watch #OncologyUnscripted: bit.ly/4aWDGAT

000

Decera Clinical Insights @deceraclinicalins.bsky.social · 21/02/2026

In this #OncologyUnscripted conversation, Dr John Marshall reflects on emerging data linking the microbiome to early-onset colon cancer risk and survival, including findings showing improved colon cancer mortality among patients taking GLP-1 receptor agonists. Watch: bit.ly/4khD0Ks

020

Decera Clinical Insights @deceraclinicalins.bsky.social · 18/02/2026

Fiber isn’t about restriction, it’s about feeding the right ecosystem 🌱 Robynne Chutkan, MD breaks down why unprocessed plant fiber fuels gut microbes, drives short-chain fatty acid production, and helps keep the immune system in balance. Watch the full episode: bit.ly/3Mc62yL

000

Decera Clinical Insights @deceraclinicalins.bsky.social · 13/02/2026

Why are more young adults being diagnosed with colorectal cancer? In this #OncologyUnscripted episode, John Marshall, MD digs into emerging research on bacteria-produced mutagens like colibactin and more... ✨ Watch the full conversation: bit.ly/4khD0Ks

000

Decera Clinical Insights @deceraclinicalins.bsky.social · 10/02/2026

How much does the gut really influence modern disease? In this #OncologyUnscripted conversation, Dr John Marshall sits down with Dr Robynne Chutkan to unpack the microbiome and more! ✨ Watch here: bit.ly/3Mc62yL

010

Decera Clinical Insights @deceraclinicalins.bsky.social · 05/02/2026

Catch up on the latest Oncology Unscripted episodes with John Marshall, MD 🍃 New conversations are now live! Watch the newest episodes here 👉 bit.ly/3M5Tady #GICancer #OncologyInsights

000

Decera Clinical Insights @deceraclinicalins.bsky.social · 02/02/2026

Early 2026, clear signal 📈 As John Marshall shares on Oncology Unscripted: colorectal cancer cases are rising, patients are younger, and screening gaps remain. New data and therapies mean urgency, now. More to come: bit.ly/3ZDiQBg #GICancer #OncologyInsights

010

Decera Clinical Insights @deceraclinicalins.bsky.social · 28/01/2026

Immunotherapy is top of mind for patients, but it doesn’t work the same for every tumor. Dr Marshall and Dr Janjigian discuss why some tumors respond less and how combination strategies may help boost immune impact. ▶️ Watch the episode: bit.ly/3LQt9P9 #OncologyUnscripted #Immunotherapy

000

Decera Clinical Insights @deceraclinicalins.bsky.social · 24/01/2026

New hope in GI cancer care 💙 In this episode of Candid Conversations, Dr John Marshall sits down with GI cancer expert Dr Yelena Janjigian for a candid discussion on the MATTERHORN study and meaningful progress in treating stomach and esophageal cancers. Watch here: bit.ly/3LQt9P9

000

Decera Clinical Insights @deceraclinicalins.bsky.social · 21/01/2026

New #OncologyUnscripted episode! Dr John Marshall on fixing the spell checker, strengthening the immune system, and the latest practice-changing cancer innovations. ▶️ Watch the full episode here: bit.ly/4qsZCu2

bit.ly

New Hope in GI Cancer Care

Dr John Marshall explores the global race to reshape cancer care through molecular innovation.

000

Decera Clinical Insights @deceraclinicalins.bsky.social · 16/01/2026

New Oncology Unscripted clip🎙️Dr John Marshall explains cancer using the body’s “spell checker”and how today’s treatments work to fix it or wake up the immune system! Watch the full episode here: bit.ly/4qsZCu2 #OncologyUnscripted #OncologyNews

000

Decera Clinical Insights @deceraclinicalins.bsky.social · 26/11/2025

We can’t wait to debut our new look at #ASH25 👀✨ Meet Decera Clinical Insights (formerly CCS + MDOutlook) in person. Find us at Booth 142. Learn more: bit.ly/48xYxKN #ASH2025 #MedicalInsights #MedicalStrategy #DeceraClinical

000

Decera Clinical Insights @deceraclinicalins.bsky.social · 21/11/2025

We’re now Decera Clinical Insights (deh-SAIR-uh), formerly MDOutlook and CCS. Our name has evolved, but our trusted expertise, real-world data, and strategic intelligence remain the same. Thank you for celebrating this next chapter with us! Learn more: corporate.deceraclinical.com?utm_source=b...

000

Decera Clinical Insights @deceraclinicalins.bsky.social · 30/10/2025

BIG NEWS! Clinical Care Solutions (CCS) is evolving into Decera Clinical Insights (deh-SAIR-uh) — a new name built for the future. Our look is changing, but your experience will stay the same. The same expert team, trusted science, and meaningful insights — now under one unified brand.

000